MedTrace Logo

Efficacy and Safety of Penpulimab Combined With Anlotinib and Chemotherapy

NCT06586242 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 194

Last updated 2024-09-19

No results posted yet for this study

Summary

This study is a two arm, randomized, prospective, multicenter study on the perioperative treatment of locally advanced resectable esophageal cancer with penpulimab combined with anlotinib hydrochloride and chemotherapy.

Conditions

  • Esophageal Cancer

Interventions

DRUG

Penpulimab;Anlotinib;albumin paclitaxel;oxaliplatin;lobaplatin

200mg, intravenous infusion, 30-60 minutes per infusion, once every 3 weeks, Penpulimab:administered on the first day of each cycle Anlotinib:Body weight \<60kg, 8mg Po, body weight ≥ 60kg, 10mg Po, D 1-14, q3w

Sponsors & Collaborators

  • Xijing Hospital

    lead OTHER

Principal Investigators

  • Liu Hong, Master · The First Affiliated Hospital of Air Force Medical University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-04-03
Primary Completion
2025-04-30
Completion
2036-04-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06586242 on ClinicalTrials.gov